4.3 Article

Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer

Journal

VIRCHOWS ARCHIV
Volume 463, Issue 4, Pages 535-545

Publisher

SPRINGER
DOI: 10.1007/s00428-013-1468-3

Keywords

Thrombospondin-4; Breast cancer; Extracellular matrix; Cancer-associated stroma

Categories

Funding

  1. National Breast Cancer Foundation, Australia
  2. Ludwig Institute of Cancer Research
  3. Cancer Council Queensland, Australia

Ask authors/readers for more resources

The thromobospondins are a family of extracellular glycoproteins that are activated during tissue remodeling processes such as embryogenesis, wound healing and cancer. Thrombospondin-4 (THBS4) is known to have roles in cellular migration, adhesion and attachment, as well as proliferation in different contexts. Data to support a role in cancer biology is increasing, including for gastrointestinal and prostate tumours. Here, using a combination of immunohistochemistry, immunofluorescence and analysis of publicly available genomic and expression data, we present the first study describing the pattern of expression of THBS4 in normal breast and breast cancer. THBS4 was located to the basement membrane of large ducts and vessels in normal breast tissue, but was absent from epithelium and extracellular matrix. There was a significant induction in expression in cancer-associated stroma relative to normal stroma (P = 0.0033), neoplastic epithelium (P < 0.0001) and normal epithelium (P < 0.0001). There was no difference in stromal expression of THBS4 between invasive ductal carcinomas (IDC) and invasive lobular carcinomas (ILC). The THBS4 mRNA levels were variable yet were generally highest in tumours typically rich in stromal content (ILC, ER positive low grade IDC; luminal A and normal-like subtypes). Genomic alterations of the THBS4 gene (somatic mutations and gene copy number) are rare suggesting this dramatic activation in expression is most likely dynamically regulated through the interaction between invading tumour cells and stromal fibroblasts in the local microenvironment. In summary, THBS4 expression in breast cancer-associated extracellular matrix contributes to the activated stromal response exhibited during tumour progression and this may facilitate invasion of tumour cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Urology & Nephrology

Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications

Arsalan Tariq, Amy E. McCart Reed, Andrew Morton, Sima Porten, Ian Vela, Elizabeth D. Williams, John W. Yaxley, Peter C. Black, Matthew J. Roberts

Summary: PSMA may be associated with pathological and survival outcomes in urothelial carcinoma (UC). PSMA PET imaging helps in detecting metastatic disease and evaluating response to systemic therapy. More research is needed to confirm these findings.

EUROPEAN UROLOGY FOCUS (2022)

Article Oncology

Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients

Kekoolani S. Visan, Richard J. Lobb, Shu Wen Wen, Justin Bedo, Luize G. Lima, Sophie Krumeich, Carlos Palma, Kaltin Ferguson, Ben Green, Colleen Niland, Nicole Cloonan, Peter T. Simpson, Amy E. McCart Reed, Sarah J. Everitt, Michael P. MacManus, Gunter Hartel, Carlos Salomon, Sunil R. Lakhani, David Fielding, Andreas Moeller

Summary: Lung cancer is a leading cause of cancer-related death worldwide and has low survival rates due to lack of early detection. A study on a lung cancer biomarker based on a simple blood test shows promising advantages for diagnostic assessment. The study identifies a specific micro-RNA, miR-3182, as a potential biomarker for lung cancer diagnosis that can be detected in the blood.

CANCERS (2022)

Article Oncology

Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer

Jodi M. Saunus, Xavier M. De Luca, Korinne Northwood, Ashwini Raghavendra, Alexander Hasson, Amy E. McCart Reed, Malcolm Lim, Samir Lal, A. Cristina Vargas, Jamie R. Kutasovic, Andrew J. Dalley, Mariska Miranda, Emarene Kalaw, Priyakshi Kalita-de Croft, Irma Gresshoff, Fares Al-Ejeh, Julia M. W. Gee, Chris Ormandy, Kum Kum Khanna, Jonathan Beesley, Georgia Chenevix-Trench, Andrew R. Green, Emad A. Rakha, Ian O. Ellis, Dan V. Nicolau, Peter T. Simpson, Sunil R. Lakhani

Summary: This study reveals the relevance of SOX10 gene in triple-negative breast cancer (TNBC) and its role in the intratumoral heterogeneity. The researchers found that the reprogramming of SOX10 is associated with genome-wide promoter methylation loss, leading to a more primitive phenotype in TNBC.

NPJ BREAST CANCER (2022)

Article Multidisciplinary Sciences

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Malcolm Lim, Nicholas Fletcher, Amy McCart Reed, Melanie Flint, Kristofer Thurecht, Jodi Saunus, Sunil R. Lakhani

Summary: Brain metastasis is a significant cause of morbidity and mortality in cancer patients, and animal models play a critical role in studying therapeutic interventions. Existing brain tumor xenografting methods lack consistency, and intracardiac injection can result in unintended extracranial growth. This study presents a mouse model of brain metastasis generated by internal carotid artery injection, which produces consistent intracranial tumors.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2022)

Editorial Material Oncology

Editorial: Molecular mechanisms in breast cancer progression and metastasis

Monica Fedele, Amy McCart Reed

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels

P. Ramarao-Milne, O. Kondrashova, A. -M. Patch, K. Nones, L. T. Koufariotis, F. Newell, V. Addala, V. Lakis, O. Holmes, C. Leonard, S. Wood, Q. Xu, P. Mukhopadhyay, M. M. Naeini, D. Steinfort, J. P. Williamson, M. Bint, C. Pahoff, P. T. Nguyen, S. Twaddell, D. Arnold, C. Grainge, F. Basirzadeh, D. Fielding, A. J. Dalley, H. Chittoory, P. T. Simpson, L. G. Aoude, V. F. Bonazzi, K. Patel, A. P. Barbour, D. A. Fennell, B. W. Robinson, J. Creaney, G. Hollway, J. V. Pearson, N. Waddell

Summary: This study explored drug repurposing opportunities using the Cancer Genome Interpreter and whole-genome sequencing. The ability of different sequencing methods, including whole-exome sequencing and comprehensive sequencing panels, to detect actionable mutations, tumor mutation burden, and microsatellite instability was compared. The results revealed shared biomarkers among different solid tumor types, with comprehensive panels identifying the majority of actionable mutations and whole-genome sequencing detecting more candidate actionable mutations.

ESMO OPEN (2022)

Review Cell Biology

Hereditary breast cancer: syndromes, tumour pathology and molecular testing

A. Sokolova, K. J. Johnstone, A. E. McCart Reed, P. T. Simpson, S. R. Lakhani

Summary: Hereditary factors, including pathogenic variants in genes such as BRCA1, BRCA2, ATM, CHEK2, etc., play a significant role in breast cancer risk. Polygenic risk, which results from carrying multiple low-penetrance breast cancer susceptibility alleles, also contributes to the risk. This review provides an overview of established breast cancer susceptibility genes, breast cancer predisposition syndromes, and discusses the implications of molecular testing and therapy in hereditary breast cancer.

HISTOPATHOLOGY (2023)

Review Oncology

NDRG1 in Cancer: A Suppressor, Promoter, or Both?

Vaibhavi Joshi, Sunil R. Lakhani, Amy E. McCart E. Reed

Summary: N-myc downregulated gene-1 (NDRG1) has been reported to have diverse roles in cancer, serving as either a metastasis suppressor, a biomarker of poor outcome, or a facilitator of disease progression. Its functions in cancer are context-dependent and pleiotropic, with its effects in breast cancer varying depending on post-translational modifications and subcellular localization.

CANCERS (2022)

Article Oncology

Evaluating Diff-Quik cytology smears for large-panel mutation testing in lung cancer-Predicting DNA content and success with low-malignant-cellularity samples

David I. Fielding, Andrew J. Dalley, Mahendra Singh, Lakshmy Nandakumar, Vanessa Lakis, Haarika Chittoory, David Fairbairn, Ann-Marie Patch, Stephen H. Kazakoff, Kaltin Ferguson, Farzad Bashirzadeh, Michael Bint, Carl Pahoff, Jung Hwa Son, Alan Hodgson, Sowmya Sharma, Nicola Waddell, Sunil R. Lakhani, Gunter Hartel, Katia Nones, Peter T. Simpson

Summary: Microscopy of Diff-Quik smears can predict DNA yield and be used for molecular diagnostics. This method can be a better alternative to traditional cell block testing.

CANCER CYTOPATHOLOGY (2023)

Article Cell Biology

BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme

Heather Thorne, Lisa Devereux, Jason Li, Kathryn Alsop, Liz Christie, Courtney T. van Geelen, Nikki Burdett, Kathleen Pishas, Noel Woodford, Jodie Leditschke, Mohamed H. M. A. Izzath, Kate Strachan, Gregory Young, Rufaro D. Jaravaza, Mohammed S. Madadin, Melanie Archer, Joanna Glengarry, Linda Iles, Ajith Rathnaweera, Clare Hampson, Khamis Almazrooei, Michael Burke, Pradeep Bandara, David Ranson, Essa Saeedi, Orla McNally, Linda Mileshkin, Anne Hamilton, Sumitra Ananda, George Au-Yeung, Yoland Antill, Shahneen Sandhu, Peter Savas, Prudence A. Francis, Stephen Luen, Sherene Loi, Ross Jennens, Clare Scott, Kate Moodie, Margaret Cummings, Andrew Reid, Amy McCart Reed, David Bowtell, Sunil R. Lakhani, Stephen Fox

Summary: This study aims to examine the metastatic patterns of breast, ovarian, and prostate cancer in germline BRCA1/2 mutation carriers and non-carriers through a rapid autopsy program. It found significant differences in the patterns of metastases in breast and ovarian cancer between BRCA1/2 carriers and non-carriers, while no significant differences were observed in prostate cancer. The findings have implications for clinical diagnostic imaging in monitoring metastases.

HISTOPATHOLOGY (2023)

Letter Medicine, General & Internal

The Queensland IMplementation of PRecision Oncology in brEast cancer (Q-IMPROvE) pilot study

Amy E. McCart Reed, Georgina Hollway, Sunil Lakhani

MEDICAL JOURNAL OF AUSTRALIA (2023)

Article Oncology

Deep spatial-omics analysis of Head & Neck carcinomas provides alternative therapeutic targets and rationale for treatment failure

Andrew Causer, Xiao Tan, Xuehan Lu, Philip Moseley, Siok M. Teoh, Natalie Molotkov, Margaret McGrath, Taehyun Kim, Peter T. Simpson, Christopher Perry, Ian H. Frazer, Benedict Panizza, Rahul Ladwa, Quan Nguyen, Jazmina L. Gonzalez-Cruz

Summary: In this study, advanced integrative spatial proteogenomic analysis was used to investigate the role of spatial determinants in cancer therapy outcomes. The researchers found that spatial transcriptomics successfully detected tumor cells and allowed for the investigation of phenotypic traits. Additionally, spatial proteomic imaging resolved the profiling of tumor infiltrating immune cells. The study also discovered clinically relevant alternative medicines based on their interaction with their matching ligand-receptor. Importantly, the researchers found that new tumors were not the product of immune checkpoint inhibitor (ICI) resistance but rather of a dose reduction due to complications.

NPJ PRECISION ONCOLOGY (2023)

Meeting Abstract Cell Biology

Breast cancer in Honiara - a retrospective audit

A. Stacey, P. Simpson, A. McCart-Reed, M. Cummings

HISTOPATHOLOGY (2022)

No Data Available